Chikungunya Virus Infection

Chikungunya Virus Infection: Rheumatological Manifestations

Clinical Overview

• Chikungunya virus infection can cause acute polyarthralgia or polyarthritis and, in some patients, prolonged inflammatory rheumatic disease.
• Rheumatological manifestations may resemble viral arthritis, rheumatoid arthritis, or spondyloarthritis.

Clinical Phases

Acute Phase: 1 to 2 Weeks

• Polyarthralgia and polyarthritis
  • Sudden onset of severe joint pain and stiffness.
  • Usually symmetric and polyarticular.
  • Commonly affects peripheral joints, including the hands, wrists, ankles, and feet.
  • Joint swelling and inflammation may resemble viral arthritis or acute rheumatoid arthritis.
• Periarticular manifestations
  • Tenosynovitis.
  • Tendinitis.
  • Myalgia.

Post-Acute and Chronic Phase: Weeks to Years

• Chronic inflammatory rheumatism
  • Persistent inflammatory polyarthritis or relapsing and remitting arthralgia and arthritis.
  • May be associated with prolonged morning stiffness, bursitis, and tenosynovitis.
  • The phenotype may resemble seronegative rheumatoid arthritis or spondyloarthritis.
  • Structural damage or deforming erosive arthritis is rare.
• Risk of chronic symptoms
  • Chronic progression occurs in 30% to 60% of infected individuals.
  • Older adults and patients with pre-existing comorbidities have increased risk.

Laboratory Findings

• Acute-phase reactants
  • Erythrocyte sedimentation rate and C-reactive protein may be elevated.
• Autoantibodies
  • Rheumatoid factor and anti-cyclic citrullinated peptide antibodies are typically negative.
  • Low-titer or incidental positivity may occasionally occur.
• Virological and serological testing
  • Chikungunya virus RT-PCR: Use for early diagnostic confirmation during the initial viremic stage.
  • Chikungunya virus IgM and IgG serology: Useful after the acute viremic period to assess post-acute exposure and convalescence.

Management

Acute Phase Management

• Prioritize rest and adequate oral hydration.
• Use paracetamol (acetaminophen) as first-line symptomatic therapy.
• Rule out dengue fever before administering nonsteroidal anti-inflammatory drugs (NSAIDs) because of bleeding risk.
• Start NSAIDs only after dengue infection has been excluded and contraindications are absent.

Persistent or Chronic Phase Management

• Continue NSAIDs when clinically indicated and tolerated.
• Consider short courses of systemic corticosteroids for severe active inflammatory flares.
• Refer patients with persistent objective inflammatory arthritis to rheumatology.
• Disease-modifying antirheumatic drugs (DMARDs)
  • Consider DMARDs for unresolved inflammatory arthritis.
  • Methotrexate has the strongest supporting clinical evidence among the options named in the source note.
  • Hydroxychloroquine may be used as an alternative or adjunct, although supporting evidence is less consistent.

Differential Diagnosis

• Rheumatoid arthritis.
• Reactive arthritis.
• Spondyloarthritis.
• Parvovirus B19 arthritis.
• Hepatitis B viral arthritis.
• Hepatitis C viral arthritis.
• Other viral arthritides, including dengue, Zika, and Ross River virus.

Practical Takeaways

• Consider chikungunya virus infection in patients with abrupt, severe, symmetric peripheral polyarthralgia or polyarthritis.
• Distinguish acute chikungunya virus infection from dengue fever before NSAID treatment.
• Persistent inflammatory arthritis warrants reassessment and possible rheumatology referral.

---

Ketamine vs Etomidate

Induction Agents: Ketamine vs Etomidate

Core Clinical Message

• Neither ketamine nor etomidate is universally hemodynamically stable.
• The induction dose, shock physiology, and preparation for peri-intubation hypotension may matter more than the drug label alone.

Etomidate

Mechanism and Hemodynamic Profile

• Etomidate is a gamma-aminobutyric acid type A (GABA-A) receptor agonist.
• It is generally considered the most cardiovascularly neutral commonly used induction agent.
• Heart rate, blood pressure, and myocardial contractility usually change little after an appropriate induction dose.
• It lowers intracranial pressure and cerebral oxygen demand.

Dose

• Typical induction dose: 0.2 to 0.3 mg/kg intravenously.

Limitations and Adverse Effects

• Etomidate inhibits 11-beta-hydroxylase and can suppress cortisol synthesis for up to 24 hours after a single dose.
  • The clinical importance of this effect, particularly in sepsis, remains debated.
• It may cause myoclonus, injection-site pain, and more nausea than some alternatives.
• It does not provide analgesia.

Ketamine

Mechanism and Hemodynamic Profile

• Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist and dissociative anesthetic.
• It usually increases heart rate and blood pressure through catecholamine release.
• Ketamine is also a direct myocardial depressant.
  • In patients with prolonged shock and depleted catecholamine reserves, direct myocardial depression may predominate and blood pressure can fall after induction.

Clinical Advantages

• Bronchodilation.
• Better preservation of respiratory drive and airway reflexes than many other induction agents.
• Analgesia.

Dose

• Typical induction dose: 1 to 2 mg/kg intravenously.
• Consider a lower dose in shock.

Intracranial Pressure

• The supplied note states that the older concern that ketamine raises intracranial pressure has largely been disproven.

Evidence Summary

• The supplied note describes a 2025 randomized trial of approximately 3,300 critically ill adults.
  • It reported no difference in 28-day mortality between ketamine and etomidate.
  • Cardiovascular collapse during intubation was reportedly more common with ketamine.
• This source summary does not provide a full citation. Verify the original study before using the result for protocol development or clinical decision-making.

Practical Selection

• Bronchospasm, asthma, or a need for analgesia: ketamine is often a useful option.
• Tenuous hemodynamics or head injury: etomidate is a reasonable option.
• Profound shock: either drug can precipitate collapse.
  • Reduce the induction dose.
  • Prepare vasopressors and resuscitation measures before induction.

Summary Takeaway

• Neither ketamine nor etomidate is reliably hemodynamically stable in every critically ill patient.
• Select the agent and dose according to the patient's physiology, airway indication, and readiness to treat peri-intubation hypotension.

---

Follow local protocols and specialist guidance for clinical decisions.

Bicarbonate in Acute Kidney Injury

Bicarbonate in Acute Kidney Injury: Clinical Lecture Notes

1. Core Principle

• Improving serum pH is a biochemical reaction, not proof that the underlying etiology is resolved.
• Raising pH does not stop acid generation, eliminate accumulated acid anions, or guarantee improved clinical outcomes.
• Avoid reflexively prescribing sodium bicarbonate simply because serum bicarbonate or pH is low.

---

2. Acidosis Etiology and Mechanisms

• Differentiate the underlying mechanism before intervention:
  • Hyperchloremic metabolic acidosis: Caused by relative chloride excess and a narrowed strong ion difference (SID). Stopping chloride-heavy fluids, switching to balanced solutions, or selectively giving bicarbonate aligns with underlying pathophysiology.
  • Lactic acidosis and ketoacidosis: Caused by organic acid overproduction. Bicarbonate fails to clear circulating lactate or ketoacid anions; restoring organ perfusion and resolving the primary trigger remain primary.
  • Uremic acidosis in AKI: Caused by impaired excretion of fixed acids (sulfates, phosphates, organic anions). Adding bicarbonate loads sodium without removing unmeasured anions.
  • Gastrointestinal or renal base loss: True bicarbonate depletion (such as severe diarrhea or proximal renal tubular acidosis) where replacement is physiologically rational.
  • Mixed acid-base disorders: Frequently coexist in critical illness and require separate diagnostic evaluation.

---

3. Physicochemical Framework (Stewart Approach)

• Traditional Henderson-Hasselbalch model:
  • Interprets pH through the balance between PaCO2 and serum HCO3-.
• Stewart approach:
  • Blood pH is governed by three independent variables:
    • PaCO2.
    • Strong Ion Difference (SID = strong cations minus strong anions, primarily Na+ minus Cl-).
    • Total nonvolatile weak acids (primarily albumin and phosphate).
  • Serum HCO3- is a dependent variable, not an independent driver.
  • Sodium bicarbonate acts by adding Na+ without a corresponding Cl-, thereby widening the SID and shifting the water dissociation equilibrium toward higher pH.
  • Practical implication: Bicarbonate therapy modifies the strong ion balance rather than merely replacing a missing buffer.

---

4. Respiratory Mechanics and Carbon Dioxide Generation

• Chemical reaction: HCO3- + H+ -> CO2 + H2O.
• Each dose of bicarbonate generates an obligatory CO2 load that requires adequate alveolar ventilation to eliminate.
• Risks in hypoventilating, exhausted, or poorly perfused patients:
  • Systemic CO2 retention.
  • Paradoxical intracellular and central nervous system acidification (lipophilic CO2 crosses cell membranes faster than charged HCO3-).
  • Serum pH may improve while intracellular and organ tissue acidosis worsens.
  • Correcting systemic acidemia blunts central respiratory drive, further aggravating hypoventilation.
• Bedside rule: Always assess whether the patient has sufficient ventilatory reserve to clear the newly generated CO2.

---

5. Clinical Benefits vs Potential Adverse Effects

• Potential benefits:
  • Temporarily mitigates severe acidemia-induced myocardial depression and vascular hyporesponsiveness.
  • Promotes intracellular potassium shift in life-threatening hyperkalemia.
  • Partially restores coagulation factor and platelet enzymatic function impaired by profound acidemia.
  • Serves as a short-term bridge while arranging definitive etiology treatment or kidney replacement therapy.
• Known adverse effects and risks:
  • Hypernatremia and hyperosmolality from high-solute load.
  • Volume overload and worsening pulmonary edema in oliguric AKI or heart failure.
  • Acute drop in ionized calcium leading to myocardial dysfunction and tetany.
  • Hypokalemia and associated cardiac arrhythmias.
  • Metabolic alkalemia from overcorrection.
  • Left shift of the oxyhemoglobin dissociation curve, impairing tissue oxygen release.
  • Intracellular paradoxical acidosis from CO2 buildup.
  • Blunted ventilatory drive.

---

6. Clinical Evidence: The BICAR-ICU Trial

• Trial design: Multicenter randomized controlled trial of 389 critically ill ICU patients with severe metabolic acidemia (pH <= 7.20), comparing 4.2% sodium bicarbonate infusion (target pH >= 7.30) against control.
• Primary outcome: No statistically significant difference in the overall composite endpoint of 28-day all-cause mortality and at least one organ failure by day 7.
• Pre-specified AKI subgroup (AKIN Stage 2-3, n = 182):
  • 28-day mortality was significantly lower in the bicarbonate arm (46% vs 63%).
  • Requirement for kidney replacement therapy was significantly reduced (51% vs 73%).
• Critical appraisal:
  • Subgroup analyses are hypothesis-generating and carry risk of false-positive findings.
  • Open-label design introduced potential clinician bias regarding triggers for initiating kidney replacement therapy.
  • Do not interpret as a universal indication to give bicarbonate to every patient with AKI and acidemia.

---

7. Appropriate Indications vs Common Misuses

• Rational indications:
  • Severe metabolic acidemia (pH < 7.15 to 7.20) in AKI with hemodynamic instability.
  • Severe hyperchloremic metabolic acidosis alongside reduction of exogenous chloride intake.
  • Critical hyperkalemia with concomitant metabolic acidosis as part of multimodal temporization.
  • Documented severe bicarbonate-wasting states (severe diarrhea, RTA).
  • Short-term bridging while preparing for emergent kidney replacement therapy.
• Frequent misuses:
  • Infusing bicarbonate instead of restoring volume, perfusion, and microcirculation in circulatory shock.
  • Repeated sodium loading in patients with heavy unmeasured anion accumulation.
  • Administering bicarbonate to patients with ventilatory failure without airway or mechanical ventilatory support.
  • Overlooking cumulative sodium load in hypervolemic or severely oliguric patients.
  • Chasing normal laboratory numbers rather than modest physiological stabilization.
  • Relying on bicarbonate infusions to delay needed kidney replacement therapy.

---

8. Bedside 5-Step Clinical Algorithm

• Step 1: Assess severity. Review pH, PaCO2, HCO3-, hemodynamic parameters, rhythm, and potassium level.
• Step 2: Determine mechanism. Calculate anion gap; evaluate chloride, lactate, ketones, albumin, and renal function.
• Step 3: Check ventilatory capacity. Verify whether spontaneous minute ventilation or mechanical ventilation can clear the extra CO2 burden.
• Step 4: Consider definitive alternatives. Restore tissue perfusion, stop chloride loading, manage sepsis or diabetic ketoacidosis, or initiate kidney replacement therapy.
• Step 5: Administer fractionated doses with discrete endpoints. Use small, incremental infusions; target a pH of roughly 7.20 to 7.25 rather than normal values; serial re-evaluation of blood gases, electrolytes, and ionized calcium is mandatory.

---

9. Summary Takeaways

• Serum HCO3- is a dependent variable; sodium bicarbonate functions by expanding the strong ion difference.
• Bicarbonate infusion produces CO2; adequate alveolar ventilation is required.
• Improving pH is not equivalent to treating the underlying cause.
• Clearing accumulated unmeasured anions in severe AKI requires kidney replacement therapy, not additional sodium load.